The New York Times, May 12, 2026: FDA Commissioner Makary resigns under pressure after offending almost everyone involved in FDA issues. NCHR president Diana Zuckerman explains that this resignation is inevitable but will be a disaster for the FDA if he is replaced by someone who is selected to primarily please tobacco, anti-abortion, and other industry lobbyists.
Read More »News That Quotes Us & Our Work
We are often quoted in major newspapers and magazines, and on well-respected TV shows, radio programs, and websites where we share our opinion on issues that matter to you and your health. Stay up to date on health news and our take on it by reading the articles in this section.
Trump’s pick for science director: a Silicon Valley investor with no science background
Salon, May 7, 2026: This Salon news story on Jim O’Neill’s controversial nomination as the first nonscientist director of the National Science Foundation (NSF) quotes NCHR’s Dr. Diana Zuckerman and other experts explaining why his lack of scientific credentials and ties to the financial world raise serious concerns about the integrity of the agency and potential conflicts of interest.
Read More »Are plastic food containers safe for storing and heating food?
BBC, March 23, 2026: This excellent BBC article on plastic food containers quotes NCHR’s Dr. Diana Zuckerman and other experts explaining why plastic containers are especially likely to leach dangerous chemicals when containing acidic foods like tomato sauce) or fatty foods (lasagna), or any hot food.
Read More »As controversial decisions mount, FDA shuns public advisory meetings
STAT News, March 9, 2026: FDA is holding very few Advisory Committee meetings in 2025-26 compared to previous years. FDA says they want to avoid undue industry influence. But these meetings also provide opportunities for a diversity of opinion says NCHR’s Diana Zuckerman, who points out that FDA is avoiding meetings with experts who disagree with what the agency has already decided to do.
Read More »Two AstraZeneca Drugs To Be Scrutinized in First FDA Cancer Advisory Panel in 9 Months
BioSpace, March 9, 2026: In April 2026 FDA will hold its first Advisory Committee meeting on cancer drugs in 9 months — the first one in FY 2026. It will discuss 2 AstraZeneca applications, one for a new drug for HR-positive HER2-negative breast cancer and the other for Truqap to treat metastatic hormone-sensitive prostate cancer.
Read More »